Has novelty in the depression pipeline hit a wall?
This article was originally published in Scrip
Executive Summary
The Phase III failure of another novel investigational product for depression, Shire's Vyvanse (lisdexamfetamine dimesylate), is raising questions over the health of the pipeline.
You may also be interested in...
Sumitomo, Otsuka Both Stand To Gain From CNS Partnership
Sumitomo’s Sunovion has made particular headway in the TAAR1 agonist field and stands to benefit from Otsuka’s CNS expertise and overseas marketing heft.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.